HIV, SA variant and BIT225, page-188

I thought I explained the risk.

This risk is - this doesn’t get fast track approval and it falls back 20 -40% down to around 5-7c ( consider progress with BIT 225)

Or it gets fast track approval and SP goes up minimum 100% that day and would likely have MC that resembles something like RAC as study starts 50c -60c (500-600%+)


At that point it would be very risky that a early buyout offer is made .

If proven effective and FDA approved well then I would say there would be extreme risk of a multi billion dollar deal.

But before you start rambling on about warnings of slow reports and just warning of likely failure.

Biotron had never been in a better position before particularly with Covid in terms of being well placed to have a drug with an existing strong safety profile to be fast tracked into a human study.
I think it would be risky to not have a parcel of shares here as it’s likely next announcement you could be paying over double.